OncoMethylome Sciences SA to Initiate a Large Colorectal Cancer Clinical Trial
OncoMethylome Sciences to Acquire Minority Interest in Signature Diagnostics AG
OncoMethylome Sciences announced that it plans to launch a large, international, multi-center colorectal cancer clinical trial. The German portion of the international trial will be managed by Signatures Diagnostics. Signature Diagnostics will receive an upfront payment plus service fees for its contribution to the clinical trial. In addition, both companies also agreed that OncoMethylome Sciences will obtain first negotiation rights on a test in development by Signature Diagnostics for predicting outcomes in colorectal cancer patients. Subject to certain conditions that are standard for this type of transactions, OncoMethylome Sciences also agreed to acquire a minority interest in Signature Diagnostics.
Additional details and financial terms of the agreement were not disclosed.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.